Opus Genetics Touts 24-Month LCA5 Vision Gains, Sets Q4 Phase 3 Dosing
IRD has more than doubled off its 52-week low of $1.7.
Summary
Opus Genetics presented updated clinical data at Retina in Rio 2026 for its two lead gene therapy programs. OPGx-BEST1 showed improved retinal sensitivity in 3 of 4 evaluable low-dose Cohort 1 patients (75%), with high-dose Cohort 2 now fully enrolled at 11 participants. OPGx-LCA5 demonstrated sustained visual acuity and light sensitivity improvements through 24 months in adults and six months in pediatric patients, with participants reporting functional gains like navigating without a cane. The company expects to begin Phase 3 dosing for OPGx-LCA5 in Q4 2026. This builds on the September 9 low-dose BEST1 data release and adds longer-term LCA5 durability plus a concrete Phase 3 timeline, reinforcing the pipeline narrative ahead of the next clinical milestone.
At the time of this announcement, IRD was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $335.3M. The 52-week trading range was $1.70 to $7.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.